Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

Mokdad, A. H., Ford, E. S., Bowman, B. A., Dietz, W. H., Vinicor, F., Bales, V. S., & Marks, J. S. (2003) · JAMA · doi:10.1001/jama.289.1.76 · Cited by 5,866 · see citing works

Host-gut microbiota metabolic interactions

Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., & Pettersson, S. (2012) · Science · doi:10.1126/science.1223813 · Cited by 4,760 · see citing works

Functional interactions between the gut microbiota and host metabolism

Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387 · see citing works

Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241 · see citing works

Identification of a nuclear receptor for bile acids

Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714 · see citing works

Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist

Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331 · see citing works

Obesity and Cardiovascular Disease

Lavie, C. J., Milani, R. V., & Ventura, H. O. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.068 · Cited by 2,326 · see citing works

Bile Acids: Natural Ligands for an Orphan Nuclear Receptor

Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274 · see citing works

Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis

Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · see citing works

Bile acids: regulation of synthesis

Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,567 · see citing works

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21025 · Cited by 1,398 · see citing works

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

Kong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391 · see citing works

Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.

Wanless, I. R., & Lentz, J. S. (1990) · Hepatology · doi:10.1002/hep.1840120505 · Cited by 1,191 · see citing works

Bile Salt Hydrolase Activity in Probiotics

Begley, M., Hill, C., & Gahan, C. G. M. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.3.1729-1738.2006 · Cited by 1,187 · see citing works

CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Febbraio, M., Hajjar, D., & Silverstein, R. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14006 · Cited by 1,171 · see citing works

Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome

Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M., & Marchesi, J. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804437105 · Cited by 1,098 · see citing works

Global challenges in liver disease

Williams, R. (2006) · Hepatology · doi:10.1002/hep.21347 · Cited by 788 · see citing works

Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance

Fang, S., Suh, J. M., Reilly, S. M., Yu, E., Osborn, O., Lackey, D., Yoshihara, E., Perino, A., Jacinto, S., Lukasheva, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3760 · Cited by 738 · see citing works

Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity

Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705 · see citing works

Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats

Zhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630 · see citing works

Structural Changes of Gut Microbiota during Berberine-Mediated Prevention of Obesity and Insulin Resistance in High-Fat Diet-Fed Rats

Zhang, X., Zhao, Y., Zhang, M., Pang, X., Xu, J., Kang, C., Li, M., Zhang, C., Zhang, Z., Zhang, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042529 · Cited by 615 · see citing works

Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut

Joyce, S. A., MacSharry, J., Casey, P. G., Kinsella, M., Murphy, E. F., Shanahan, F., Hill, C., & Gahan, C. G. M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1323599111 · Cited by 604 · see citing works

Interactions Between Gut Microbiota and Host Metabolism Predisposing to Obesity and Diabetes

Musso, G., Gambino, R., & Cassader, M. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-012510-175505 · Cited by 598 · see citing works

Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine Published, JLR Papers in Press, August 24, 2007.

Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S., & Gonzalez, F. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 575 · see citing works

Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma.

Vaughan, T. L., Davis, S., Kristal, A. R., & Thomas, D. B. (1995) · PubMed · Cited by 516 · see citing works

Epidemiology of non-alcoholic fatty liver disease in China

Fan, J., & Farrell, G. C. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.10.010 · Cited by 501 · see citing works

The role of the gut microbiota in nonalcoholic fatty liver disease

Abu-Shanab, A., & Quigley, E. M. M. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.172 · Cited by 457 · see citing works

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

Kong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456 · see citing works

Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease

Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., Maria, S. D., Cartenı̀, M., & Nardone, G. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.02.007 · Cited by 448 · see citing works

FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway

Potthoff, M. J., Boney-Montoya, J., Choi, M., He, T., Sunny, N. E., Satapati, S., Suino-Powell, K., Xu, H. E., Gerard, R. D., Finck, B. N., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.03.019 · Cited by 431 · see citing works

GI Epidemiology: nonalcoholic fatty liver disease

Angulo, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03246.x · Cited by 370 · see citing works

Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance

James, O., & Day, C. P. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80073-1 · Cited by 370 · see citing works

Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats

Liu, Y.-T., Hao, H.-P., Xie, H.-G., Lai, L., Wang, Q., Liu, C.-X., & Wang, G.-J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.033936 · Cited by 356 · see citing works

Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice

Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., & Moschetta, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.032 · Cited by 356 · see citing works

Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine

Brusq, J.-M. G., Ancellin, N., Grondin, P., Guillard, R., Martin, S., Saintillan, Y., & Issandou, M. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600020-jlr200 · Cited by 344 · see citing works

FXR, a multipurpose nuclear receptor

Lee, F. Y., Lee, H., Hubbert, M. L., Edwards, P. A., & Zhang, Y. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.08.002 · Cited by 344 · see citing works

Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity

Mueller, M., Thorell, A., Claudel, T., Jha, P., Köfeler, H. C., Lackner, C., Hoesel, B., Fauler, G., Stojaković, T., Einarsson, C., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.034 · Cited by 314 · see citing works

Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism

Trauner, M. A., Claudel, T., Fickert, P., Moustafa, T., & Wagner, M. (2010) · Digestive Diseases · doi:10.1159/000282091 · Cited by 310 · see citing works

Significance of bile salt hydrolytic activities of lactobacilli

Smet, I. D., Hoorde, L. V., Woestyne, M. V., Christiaens, H., & Verstraete, W. (1995) · Journal of Applied Bacteriology · doi:10.1111/j.1365-2672.1995.tb03140.x · Cited by 307 · see citing works

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290 · see citing works

Identification of the DNA Binding Specificity and Potential Target Genes for the Farnesoid X-activated Receptor

Laffitte, B. A., Kast-Woelbern, H. R., Nguyen, C., Zavacki, A. M., Moore, D. D., & Edwards, P. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10638 · Cited by 275 · see citing works

Tissue Distribution of Berberine and Its Metabolites after Oral Administration in Rats

Tan, X.-S., Ma, J.-Y., Feng, R., Ma, C., Chen, W.-J., Sun, Y.-P., Fu, J., Huang, M., He, C.-Y., Shou, J.-W., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077969 · Cited by 266 · see citing works

Lowering Bile Acid Pool Size with a Synthetic Farnesoid X Receptor (FXR) Agonist Induces Obesity and Diabetes through Reduced Energy Expenditure

渡辺, 光., Horai, Y., Houten, S. M., Morimoto, K., Sugizaki, T., Arita, E., Mataki, C., Sato, H., Tanigawara, Y., Schoonjans, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248203 · Cited by 255 · see citing works

Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet

Kong, B., Luyendyk, J. P., Tawfik, O. W., & Guo, G. L. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.144600 · Cited by 211 · see citing works

Obesity as a risk factor for certain types of cancer

Carroll, K. K. (1998) · Lipids · doi:10.1007/s11745-998-0305-8 · Cited by 188 · see citing works

Effects and Action Mechanisms of Berberine and Rhizoma coptidis on Gut Microbes and Obesity in High-Fat Diet-Fed C57BL/6J Mice

Xie, W., Gu, D., Li, J., Cui, K., & Zhang, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024520 · Cited by 183 · see citing works

Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity

Smet, I. D., Boever, P. D., & Verstraete, W. (1998) · British Journal Of Nutrition · doi:10.1079/bjn19980030 · Cited by 182 · see citing works

FXR regulates organic solute transporters α and β in the adrenal gland, kidney, and intestine

Lee, H. C., Zhang, Y., Lee, F. Y., Nelson, S. F., Gonzalez, F. J., & Edwards, P. A. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500417-jlr200 · Cited by 178 · see citing works

Synthetic FXR Agonist GW4064 Prevents Diet-Induced Hepatic Steatosis and Insulin Resistance

Ma, Y., Huang, Y., Yan, L., Gao, M., & Liu, D. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0986-7 · Cited by 166 · see citing works

PPARα-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis

Zhou, X., Cao, L., Jiang, C., Xie, Y., Cheng, X., Krausz, K. W., Qi, Y., Sun, L., Shah, Y. M., Gonzalez, F. J., et al. (2014) · Nature Communications · doi:10.1038/ncomms5573 · Cited by 163 · see citing works

Role of Scavenger Receptor A and CD36 in Diet-Induced Nonalcoholic Steatohepatitis in Hyperlipidemic Mice

Bieghs, V., Wouters, K., van Gorp, P. J., Gijbels, M. J., de Winther, M. P. J., Binder, C. J., Lütjohann, D., Febbraio, M., Moore, K. J., van Bilsen, M., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.02.051 · Cited by 160 · see citing works

Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats

Chang, X., Yan, H., Jing, F., Jiang, M., Zhu, H., Lu, D., & Gao, X. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001958 · Cited by 157 · see citing works

CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism

Febbraio, M., Hajjar, D. P., & Silverstein, R. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200114006 · Cited by 147 · see citing works

Berberine ameliorates nonalcoholic fatty liver disease by a global modulation of hepatic mRNA and lncRNA expression profiles

Yuan, X., Wang, J., Tang, X., Li, Y., Xia, P., & Gao, X. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0383-6 · Cited by 127 · see citing works

Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption

Wang, Y., Yi, X., Ghanam, K., Zhang, S., Zhao, T.-T., & Zhu, X. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.013 · Cited by 112 · see citing works

Berberine Ameliorates Hepatic Steatosis and Suppresses Liver and Adipose Tissue Inflammation in Mice with Diet-induced Obesity

Guo, T., Woo, S., Guo, X., Li, H., Zheng, J., Botchlett, R. E., Liu, M., Pei, Y., Xu, H., Cai, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep22612 · Cited by 111 · see citing works

A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine

Gu, S., Cao, B., Sun, R., Tang, Y., Paletta, J. L., Wu, X., Liu, L., Zha, W., Zhao, C., Li, Y., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00500g · Cited by 82 · see citing works

FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation

Yao, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14430 · Cited by 78 · see citing works

Fibroblast Growth Factor 19 Treatment Ameliorates Disruption of Hepatic Lipid Metabolism in Farnesoid X Receptor (Fxr)-Null Mice

Miyata, M., Sakaida, Y., Matsuzawa, H., Yoshinari, K., & Yamazoe, Y. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1885 · Cited by 77 · see citing works

Intestinal microflora and metabolic diseases

Serino, M., Luche, E., Chabo, C., Amar, J., & Burcelin, R. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.003 · Cited by 77 · see citing works

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells

Cao, B., Li, M., Zha, W., Zhao, Q., Gu, R., Liu, L., Shi, J., Zhou, J. L., Zhou, F., Wu, X., et al. (2013) · Metabolomics · doi:10.1007/s11306-013-0517-x · Cited by 75 · see citing works

The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease.

Polyzos, S. A., Kountouras, J., & Zavos, C. (2009) · Europe PMC (PubMed Central) · Cited by 55 · see citing works

Analysis of bile acid‐induced regulation of FXR target genes in human liver slices

Jung, D., Elferink, M. G. L., Stellaard, F., & Groothuis, G. M. M. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01393.x · Cited by 53 · see citing works

Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters

Wang, Y., Jia, X., Ghanam, K., Beaurepaire, C., Zidichouski, J. A., & Miller, L. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.08.050 · Cited by 51 · see citing works

Correction: A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine

Gu, S., Cao, B., Sun, R., Tang, Y., Paletta, J. L., Wu, X., Liu, L., Zha, W., Zhao, C., Li, Y., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb90042a · Cited by 49 · see citing works

An in vitro metabolic system of gut flora and the metabolism of ginsenoside Rg3 and cholic acid

Zhao, C., Sun, R., Cao, B., Gu, S., Zhao, J., Liu, L., Wang, X., Zha, W., Yu, X., Xiao, W., et al. (2013) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-013-0143-z · Cited by 14 · see citing works

[Comparative study of pharmacokinetics and tissue distribution of 8-cetylberberine and berberine in rats].

Hu, Y., Chen, C., Zou, Z., Li, X., & Ye, X. (2014) · PubMed · Cited by 7 · see citing works

Biological properties and clinical applications of berberine

Song, D., Hao, J., & Fan, D. (2020) · Frontiers of Medicine · doi:10.1007/s11684-019-0724-6 · Cited by 510 · see citing works

Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

Feng, X., Sureda, A., Jafari, S., Memariani, Z., Tewari, D., Annunziata, G., Barrea, L., Hassan, S. T. S., Šmejkal, K., Malaník, M., et al. (2019) · Theranostics · doi:10.7150/thno.30787 · Cited by 465 · see citing works

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

Zhang, Y., Gu, Y., Ren, H., Wang, S., Zhong, H., Zhao, X., Ma, J., Gu, X., Xue, Y., Huang, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18414-8 · Cited by 380 · see citing works

Berberine pharmacology and the gut microbiota: A hidden therapeutic link

Habtemariam, S. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104722 · Cited by 352 · see citing works

Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion

Hu, H., Shao, W., Liu, Q., Liu, N., Wang, Q., Xu, J., Zhang, X., Weng, Z., Lu, Q., Jiao, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27758-8 · Cited by 288 · see citing works

Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway

Zhu, X., Bian, H., Wang, L., Sun, X., Xu, X., Yan, H., Xia, M., Chang, X., Lü, Y., Li, Y., et al. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.019 · Cited by 274 · see citing works

Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence

Xu, X., Yi, H., Wu, J., Kuang, T., Zhang, J., Li, Q., Du, H., Xu, T., Jiang, G., & Fan, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110984 · Cited by 246 · see citing works

Impact of Gut Microbiota and Microbiota-Related Metabolites on Hyperlipidemia

Jia, X., Xu, W., Zhang, L., Li, X., Wang, R., & Wu, S. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.634780 · Cited by 233 · see citing works

Herbal drug discovery for the treatment of nonalcoholic fatty liver disease

Yan, T., Yan, N., Wang, P., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.11.017 · Cited by 225 · see citing works

Oxidative stress, nutritional antioxidants and beyond

Guo, Q., Li, F., Duan, Y., Wen, C., Wang, W., Zhang, L., Huang, R., & Yin, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9591-5 · Cited by 154 · see citing works

Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome

Li, X., Su, C., Jiang, Z., Yang, Y., Zhang, Y., Yang, M., Zhang, X., Du, Y., Zhang, J., Wang, L., et al. (2021) · npj Biofilms and Microbiomes · doi:10.1038/s41522-021-00205-8 · Cited by 153 · see citing works

Interactions between gut microbiota and berberine, a necessary procedure to understand the mechanisms of berberine

Cheng, H., Liu, J., Tan, Y., Feng, W., & Peng, C. Y. (2021) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2021.10.003 · Cited by 137 · see citing works

Effects of Berberine on the Gastrointestinal Microbiota

Zhang, L., Wu, X., Yang, R., Chen, F., Liao, Y., Zhu, Z., Wu, Z., Sun, X. H., & Wang, L. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.588517 · Cited by 131 · see citing works

Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites

Ding, Y., Yanagi, K., Cheng, C., Alaniz, R. C., Lee, K., & Jayaraman, A. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.029 · Cited by 122 · see citing works

The pharmacological activity of berberine, a review for liver protection

Zhou, M., Deng, Y., Liu, M., Liao, L., Dai, X., Guo, C., Zhao, X., He, L., Peng, C. Y., & Li, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173655 · Cited by 106 · see citing works

Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation

Tian, Y., Cai, J., Gui, W., Nichols, R. G., Koo, I., Zhang, J., Anitha, M., & Patterson, A. D. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083691 · Cited by 107 · see citing works

Berberine, a Herbal Metabolite in the Metabolic Syndrome: The Risk Factors, Course, and Consequences of the Disease

Och, A., Och, M., Nowak, R., Podgórska, D., & Podgórski, R. (2022) · Molecules · doi:10.3390/molecules27041351 · Cited by 104 · see citing works

Berberine regulates fecal metabolites to ameliorate 5-fluorouracil induced intestinal mucositis through modulating gut microbiota

Chen, H., Zhang, F., Li, R., Liu, Y., Wang, X., Zhang, X., Xu, C., Li, Y., Guo, Y., & Yao, Q. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109829 · Cited by 98 · see citing works

Exogenous bile acids regulate energy metabolism and improve the health condition of farmed fish

Wang, L., Sagada, G., Wang, C., Liu, R., Li, Q., Zhang, C., & Yan, Y. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738852 · Cited by 98 · see citing works

Nuciferine Protects Against High-Fat Diet-Induced Hepatic Steatosis via Modulation of Gut Microbiota and Bile Acid Metabolism in Rats

Sun, J., Fan, J., Li, T., Yan, X., & Jiang, Y. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c04817 · Cited by 97 · see citing works

Obesity: pathophysiology and therapeutic interventions

Kong, Y., Yang, H., Nie, R., Zhang, X., Zuo, F., Zhang, H., & Nian, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00264-9 · Cited by 89 · see citing works

Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients

Wu, C., Zhao, Y. L., Zhang, Y., Yang, Y., Su, W., Yang, Y., Sun, L., Zhang, F., Yu, J., Wang, Y., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.011 · Cited by 83 · see citing works

The gut microbiota modulator berberine ameliorates collagen‐induced arthritis in rats by facilitating the generation of butyrate and adjusting the intestinal hypoxia and nitrate supply

Yue, M., Tao, Y., Fang, Y., Lian, X., Zhang, Q., Xia, Y., Wei, Z., & Dai, Y. (2019) · The FASEB Journal · doi:10.1096/fj.201900425rr · Cited by 78 · see citing works

Berberine Prevents Disease Progression of Nonalcoholic Steatohepatitis through Modulating Multiple Pathways

Wang, Y., Tai, Y., Zhao, D., Zhang, Y., Yan, J., Kakiyama, G., Wang, X., Gurley, E. C., Liu, J., Liu, J., et al. (2021) · Cells · doi:10.3390/cells10020210 · Cited by 72 · see citing works

The berberine-enriched gut commensal Blautia producta ameliorates high-fat diet (HFD)-induced hyperlipidemia and stimulates liver LDLR expression

Yang, Y., Wang, Q., Xu, W., Yu, J., Zhang, H., & Wu, C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113749 · Cited by 69 · see citing works

The mechanism of berberine alleviating metabolic disorder based on gut microbiome

Wang, H., Zhang, H., Gao, Z., Zhang, Q., & Gu, C. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.854885 · Cited by 69 · see citing works

Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer

Girisa, S., Henamayee, S., Parama, D., Rana, V., Dutta, U., & Kunnumakkara, A. B. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00035-2 · Cited by 66 · see citing works

Berberine Influences Blood Glucose via Modulating the Gut Microbiome in Grass Carp

Pan, H., Li, Z., Xie, J., Liu, D., Wang, H., Yu, D., Zhang, Q., Hu, Z., & Shi, C. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01066 · Cited by 66 · see citing works

Gastrointestinal biotransformation of phytochemicals: Towards futuristic dietary therapeutics and functional foods

Singh, B., Mal, G., Sharma, D., Sharma, R., Antony, C. P., & Kalra, R. S. (2020) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2020.09.022 · Cited by 64 · see citing works

Research progress on pharmacological effects and bioavailability of berberine

Cui, Y., Zhou, Q., Jin, M., Jiang, S., Shang, P., Dong, X., & Li, L. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03199-0 · Cited by 70 · see citing works

The Effects of Berberine on the Gut Microbiota in Apc min/+ Mice Fed with a High Fat Diet

Wang, H., Guan, L., Li, J., Lai, M., & Wen, X. (2018) · Molecules · doi:10.3390/molecules23092298 · Cited by 58 · see citing works

Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues

Mandal, S. K., Maji, A. K., Mishra, S. K., Ishfaq, P. M., Devkota, H. P., Sanches-Silva, A. T., & Das, N. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105085 · Cited by 58 · see citing works

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation

Shu, X., Li, M., Cao, Y., Li, C., Zhou, W., Ji, G., & Zhang, L. R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.750826 · Cited by 57 · see citing works

Metabolites of Gut Microbiota and Possible Implication in Development of Diabetes Mellitus

Guo, Z., Pan, J., Zhu, H., & Chen, Z. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c07851 · Cited by 57 · see citing works

Targeting gut microbial bile salt hydrolase (BSH) by diet supplements: new insights into dietary modulation of human health

Yang, Y., & Wu, C. (2022) · Food & Function · doi:10.1039/d2fo01252a · Cited by 57 · see citing works

Effectiveness and safety of Bifidobacterium and berberine in human hyperglycemia and their regulatory effect on the gut microbiota: a multi-center, double-blind, randomized, parallel-controlled study

Ming, J., Yu, X., Xu, X., Wang, L., Ding, C., Wang, Z., Xie, X., Li, S., Yang, W., Luo, S., et al. (2021) · Genome Medicine · doi:10.1186/s13073-021-00942-7 · Cited by 52 · see citing works

Berberine Improves Glucose and Lipid Metabolism in HepG2 Cells Through AMPKα1 Activation

Ren, G., Guo, J., Qian, Y., Kong, W., & Jiang, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00647 · Cited by 57 · see citing works

Orally administered berberine ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting activation of PPAR-γ and subsequent expression of HGF in colons

Guan, C., Qiao, S., Lv, Q., Cao, N., Wang, K., Dai, Y., & Wei, Z. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.02.001 · Cited by 54 · see citing works

The pathophysiological function of non-gastrointestinal farnesoid X receptor

Yan, N., Yan, T., Xia, Y., Hao, H., Wang, G., & Gonzalez, F. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107867 · Cited by 54 · see citing works

Efficacy of berberine in treatment of rheumatoid arthritis: From multiple targets to therapeutic potential

Huang, D., Wu, F., Zhang, A., Sun, H. J., & Wang, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105667 · Cited by 53 · see citing works

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor

She, J., Gu, T., Pang, X., Liu, Y., Tang, L. Y., & Zhou, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772435 · Cited by 52 · see citing works

Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease

Yu, Q., Jiang, Z., & Zhang, L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.005 · Cited by 52 · see citing works

Pharmacokinetics and Pharmacological Activities of Berberine in Diabetes Mellitus Treatment

Han, Y., Xiang, Y., Shi, Y., Tang, X., Pan, L., Gao, J., Bi, R., & Lai, X. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/9987097 · Cited by 51 · see citing works

Enterohepatic circulation of bile acids and their emerging roles on glucolipid metabolism

Chen, M., Liu, C., Wan, Y., Yang, L., Jiang, S., Qian, D., & Duan, J. (2020) · Steroids · doi:10.1016/j.steroids.2020.108757 · Cited by 51 · see citing works

The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis

Sun, R., Kong, B., Yang, N., Cao, B., Feng, D., Yu, X., Ge, C., Feng, S., Fei, F., Huang, J., et al. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000215 · Cited by 50 · see citing works

Berberine prevents NAFLD and HCC by modulating metabolic disorders.

Lin, X., Zhang, J.-H., Chu, Y., Nie, Q.-Y., & Zhang, J.-M. (2024) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2024.108593 · Cited by 52 · see citing works

Gut microbiota as a target for prevention and treatment of type 2 diabetes: Mechanisms and dietary natural products

Xia, F., Wen, L., Ge, B., Li, Y., Li, F., & Zhou, B. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i8.1146 · Cited by 51 · see citing works

Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora

Liu, X., Wang, L., Tan, S., Chen, Z., Wu, B., & Wu, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.814871 · Cited by 44 · see citing works

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review

Cai, Y., Yang, Q., Yu, Y., Yang, F., Bai, R., & Fan, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1283784 · Cited by 46 · see citing works

Role of CD36 in central nervous system diseases

Feng, M., Zhou, Q., Xie, H., Liu, C., Zheng, M., Zhang, S., Zhou, S., & Zhao, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.380821 · Cited by 43 · see citing works

Berberine: A Promising Natural Isoquinoline Alkaloid for the Development of Hypolipidemic Drugs

Li, D., Yu, P., Xiao, W., Wang, Z., & Zhao, L.-G. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200908165913 · Cited by 44 · see citing works

L‐Theanine regulates lipid metabolism by modulating gut microbiota and bile acid metabolism

Xu, W., Kong, Y., Zhang, T., Gong, Z., & Xiao, W. (2022) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.12222 · Cited by 41 · see citing works

Preventive and Therapeutic Roles of Berberine in Gastrointestinal Cancers

Hu, S., Zhao, R., Liu, Y., Chen, J., Zheng, Z., & Wang, S. (2019) · BioMed Research International · doi:10.1155/2019/6831520 · Cited by 41 · see citing works

Multi-Pharmacology of Berberine in Atherosclerosis and Metabolic Diseases: Potential Contribution of Gut Microbiota

Yang, S., Li, D., Yu, Z., Li, Y., & Wu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.709629 · Cited by 40 · see citing works

Cholesterol-lowering effect of bile salt hydrolase from a Lactobacillus johnsonii strain mediated by FXR pathway regulation

Zhu, H., Zhao, F., Zhang, W., Xia, W., Chen, Y., Liu, Y., Fan, Z., Zhang, Y., & Yang, Y. (2021) · Food & Function · doi:10.1039/d1fo03143k · Cited by 40 · see citing works

Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis

Li, H., Xi, Y., Xin, X., Tian, H., & Hu, Y. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00454-y · Cited by 40 · see citing works

Berberine compounds improves hyperglycemia via microbiome mediated colonic TGR5-GLP pathway in db/db mice

Li, M., Zhou, W., Dang, Y., Li, C., Ji, G., & Zhang, L. R. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110953 · Cited by 40 · see citing works

Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease

Wang, Y.-H., Chen, X., Bai, Y.-Z., Gao, P., Yang, Z. R., Guo, Q., Lu, Y., Zheng, J., Liu, D., Yang, J., et al. (2024) · Theranostics · doi:10.7150/thno.89602 · Cited by 39 · see citing works

Add-on therapy with traditional Chinese medicine: An efficacious approach for lipid metabolism disorders

Zhang, Y., Kishi, H., & Kobayashi, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.06.004 · Cited by 38 · see citing works

Obesity-Related Asthma: Immune Regulation and Potential Targeted Therapies

Yuan, Y., Ran, N., Xiong, L., Wang, G., Guan, X., Wang, Z., Guo, Y., Pang, Z., Fang, K., Lu, J., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/1943497 · Cited by 37 · see citing works

Using herbal medicine to target the “microbiota-metabolism-immunity” axis as possible therapy for cardiovascular disease

Wang, A., Dongcheng, C., Zhang, H., Li, Q., Yan, Z., Qiu, Y., Xu, H., & Keji, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.02.018 · Cited by 37 · see citing works

Mechanism and Basis of Traditional Chinese Medicine Against Obesity: Prevention and Treatment Strategies

Zhang, C., Sheng, J., Xie, W., Luo, X., Xue, Y., Xu, G., & Chen, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.615895 · Cited by 40 · see citing works

Withaferin A alleviates fulminant hepatitis by targeting macrophage and NLRP3

Xia, Y., Wang, P., Yan, N., Gonzalez, F. J., & Yan, T. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03243-w · Cited by 36 · see citing works

Role of Gut Microbiota in the Pharmacological Effects of Natural Products

Pan, C., Qing-long, G., & Lu, N. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/2682748 · Cited by 35 · see citing works

Regulation of in vivo delivery of nanomedicines by herbal medicines

Guan, J., Chen, W., Yang, M., Wu, E., Qian, J., & Zhan, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.015 · Cited by 35 · see citing works

Bioactive dietary components—Anti‐obesity effects related to energy metabolism and inflammation

Silva, C. B., Zingg, J.-M. A., Fassini, P. G., & Suen, V. M. M. (2022) · BioFactors · doi:10.1002/biof.1921 · Cited by 35 · see citing works

Identification of an Oleanane-Type Triterpene Hedragonic Acid as a Novel Farnesoid X Receptor Ligand with Liver Protective Effects and Anti-inflammatory Activity

Lu, Y., Zheng, W., Lin, S., Guo, F., Zhu, Y., Wei, Y., Liu, X., Jin, S., Jin, L., & Li, Y. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.109900 · Cited by 34 · see citing works

Study on the Antihypertensive Mechanism of Astragalus membranaceus and Salvia miltiorrhiza Based on Intestinal Flora-Host Metabolism

Han, C., Jiang, Y., Li, W., Liu, Y., & Qi, Z.-Q. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/5418796 · Cited by 34 · see citing works

Berberine alters gut microbial function through modulation of bile acids

Wolf, P. G., Devendran, S., Doden, H. L., Ly, L. K., Moore, T., Takei, H., Nittono, H., Murai, T., Kurosawa, T., Chlipala, G. E., et al. (2021) · BMC Microbiology · doi:10.1186/s12866-020-02020-1 · Cited by 34 · see citing works

Salvia-Nelumbinis naturalis extract protects mice against MCD diet-induced steatohepatitis via activation of colonic FXR-FGF15 pathway

Li, C., Zhou, W., Li, M., Shu, X., Zhang, L. R., & Ji, G. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111587 · Cited by 35 · see citing works

Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies

Sun, A., Yang, H., Li, T., Luo, J., Zhou, L., Chen, R., Han, L., & Lin, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1368950 · Cited by 33 · see citing works

Berberine ameliorates blockade of autophagic flux in the liver by regulating cholesterol metabolism and inhibiting COX2-prostaglandin synthesis

Sun, H., Liu, Q., Hu, H., Jiang, Y., Shao, W., Wang, Q., Jiang, Z., & Gu, A. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0890-5 · Cited by 33 · see citing works

The crosstalk between NLRP3 inflammasome and gut microbiome in atherosclerosis

Zhang, X., Yu, Z., Chen, J., Li, X., Wang, Z.-P., Wu, M., & Liu, L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106289 · Cited by 33 · see citing works

Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota

Cai, T., Song, X., Xu, X., Dong, L., Liang, S., Xin, M., Huang, Y., Zhu, L., Li, T., Wang, X., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1323261 · Cited by 32 · see citing works

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases

Wu, J., Chen, J., & Chen, J. (2020) · Canadian Respiratory Journal · doi:10.1155/2020/9137251 · Cited by 31 · see citing works

A review: antimicrobial properties of several medicinal plants widely used in Traditional Chinese Medicine

Chen, K., Wu, W., Hou, X., Yang, Q., & Li, Z. (2021) · Food Quality and Safety · doi:10.1093/fqsafe/fyab020 · Cited by 31 · see citing works

Tibet Kefir Milk Regulated Metabolic Changes Induced by High-Fat Diet via Amino Acids, Bile Acids, and Equol Metabolism in Human-Microbiota-Associated Rats

Gao, J., Mao, K., Wang, X., Mi, S., Fu, M., Li, X., Xiao, J., Simal‐Gándara, J., & Sang, Y. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c02430 · Cited by 31 · see citing works

Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity

Fan, X., Pan, H., Li, Y., Guo, R., Leung, E. L., & Liu, L. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.06.010 · Cited by 29 · see citing works

Potential of Intestine-Selective FXR Modulation for Treatment of Metabolic Disease

van Zutphen, T., Bertolini, A., de Vries, H. D., Bloks, V. W., de Boer, J. F., Jonker, J. W., & Kuipers, F. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_233 · Cited by 30 · see citing works

Withaferin A in the Treatment of Liver Diseases: Progress and Pharmacokinetic Insights

Xia, Y., Yan, M., Wang, P., Hamada, K., Yan, N., Hao, H., Gonzalez, F. J., & Yan, T. (2021) · Drug Metabolism and Disposition · doi:10.1124/dmd.121.000455 · Cited by 29 · see citing works

Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence

Kong, Y., Yang, H., Nie, R., Zhang, X., Zhang, H., & Nian, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02738-6 · Cited by 40 · see citing works

A UPLC-MS/MS-based metabolomics analysis of the pharmacological mechanisms of rabdosia serra against cholestasis

Zhang, K., Yao, Y., Wang, M., Liu, F., Wang, Q., Ma, H., Xie, Y., Ma, Y., Dai, P., Zhu, C., et al. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153683 · Cited by 28 · see citing works

Influence of Dietary Berberine on Liver Immune Response and Intestinal Health of Black Sea Bream (Acanthopagrus schlegelii) Fed with Normal and High-Lipid Diets

Wang, L., Sagada, G., Xu, B., Zhang, J., & Shao, Q. (2022) · Aquaculture Nutrition · doi:10.1155/2022/6285266 · Cited by 28 · see citing works

Berberine Protects against High-Energy and Low-Protein Diet-Induced Hepatic Steatosis: Modulation of Gut Microbiota and Bile Acid Metabolism in Laying Hens

Wang, C., Yang, Y., Chen, J., Dai, X., Xing, C., Zhang, C., Cao, H., Guo, X., Hu, G., & Zhuang, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417304 · Cited by 27 · see citing works

Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease

Gillard, J., & Leclercq, I. A. (2023) · Clinical Science · doi:10.1042/cs20220697 · Cited by 27 · see citing works

Hop bioactive compounds in prevention of nutrition-related noncommunicable diseases

Iniguez, A. B., & Zhu, M. J. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1767537 · Cited by 26 · see citing works

Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia

Chou, W.-L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105693 · Cited by 29 · see citing works

Preclinical Evidence of Berberine on Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Animal Studies

Ren, S., Ma, X., Wang, R., Liu, H., Wei, Y., Wei, S., Jing, M., & Zhao, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.742465 · Cited by 26 · see citing works

Chlorogenic Acid Inhibits Lipid Deposition by Regulating the Enterohepatic FXR‐FGF15 Pathway

Ye, X., Li, J., Gao, Z., Wang, D., Wang, H., & Wu, J. (2022) · BioMed Research International · doi:10.1155/2022/4919153 · Cited by 26 · see citing works

Effect of dietary honeysuckle (Lonicera caerulea L.) supplementation on lipid metabolism, immunity and intestinal microbiota in grass carp (Ctenopharyngodon idellus)

Meng, X., Cao, H., Li, H., Li, K., Yang, G., Zhang, Y., Chang, X., Zhang, X., & Zhang, J. (2022) · Aquaculture Reports · doi:10.1016/j.aqrep.2022.101063 · Cited by 26 · see citing works

Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus

He, Q., Dong, H., Guo, Y., Gong, M., Xia, Q., Lu, F., & Wang, D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1074348 · Cited by 26 · see citing works

Microarray Expression Profiling and Raman Spectroscopy Reveal Anti-Fatty Liver Action of Berberine in a Diet-Induced Larval Zebrafish Model

Chen, B., Zheng, Y., Zhang, M., Han, Y., Zhang, J., & Chang-qin, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01504 · Cited by 26 · see citing works

Berberine in fish nutrition: Impact on hepatoenteric health, antioxidative and immune status

Wang, L., Sagada, G., Wang, C., Gao, C. Y., Wang, B., Shao, Q., & Yan, Y. (2022) · Frontiers in Marine Science · doi:10.3389/fmars.2022.967748 · Cited by 22 · see citing works

Anti-obesity Properties of Phytochemicals: Highlighting their Molecular Mechanisms against Obesity

Poulios, E., Koukounari, S., Psara, E., Vasios, G. K., Sakarikou, C., & Giaginis, C. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230517124033 · Cited by 24 · see citing works

Berberine as a Bioactive Alkaloid: Multi-Omics Perspectives on Its Role in Obesity Management

Zieniuk, B., & Pawełkowicz, M. E. (2025) · Metabolites · doi:10.3390/metabo15070467 · Cited by 20 · see citing works

Intestinal farnesoid X receptor mediates the effect of dietary berberine on lipid accumulation in grass carp (Ctenopharyngodon idella)

Tian, J., Jin, Y.-Q., Yu, E., Sun, J., Xia, Y. L., Zhang, K., Li, Z., Gong, W., Wang, G.-J., & Xie, J. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738055 · Cited by 20 · see citing works

Natural compounds as obesity pharmacotherapies

Zhao, X.-Y., Wang, J.-Q., Neely, G. G., Shi, Y., & Wang, Q.-P. (2023) · Phytotherapy Research · doi:10.1002/ptr.8083 · Cited by 17 · see citing works

Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism

Liu, Y., Wang, H., Geng, Y.-H., Han, L., Tu, S., & Wang, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1112088 · Cited by 19 · see citing works

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology

Yang, X., Lü, M., You, L., Gen, H., Yuan, L., Tian, T., Li, C., Xu, K., Hou, J., & Lei, M. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00470-x · Cited by 18 · see citing works

The human gut microbiome – a new and exciting avenue in cardiovascular drug discovery

Du, Y., Li, X., Su, C., Wang, L., Jiang, J., & Hong, B. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1638909 · Cited by 20 · see citing works

A metabolomic and pharmacokinetic study on the mechanism underlying the lipid-lowering effect of orally administered berberine

Gu, S., Cao, B., Sun, R., Tang, Y., Paletta, J. L., Wu, X., Liu, L., Zha, W., Zhao, C., Li, Y., et al. (2014) · Molecular BioSystems · doi:10.1039/c4mb00500g · Cited by 82 · see citing works

Intestinal farnesoid X receptor mediates the effect of dietary berberine on lipid accumulation in grass carp (Ctenopharyngodon idella)

Tian, J., Jin, Y.-Q., Yu, E., Sun, J., Xia, Y. L., Zhang, K., Li, Z., Gong, W., Wang, G.-J., & Xie, J. (2022) · Aquaculture · doi:10.1016/j.aquaculture.2022.738055 · Cited by 20 · see citing works

Berberine Directly Affects the Gut Microbiota to Promote Intestinal Farnesoid X Receptor Activation

Tian, Y., Cai, J., Gui, W., Nichols, R. G., Koo, I., Zhang, J., Anitha, M., & Patterson, A. D. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.083691 · Cited by 107 · see citing works

The Hypoglycemic Effect of Berberine and Berberrubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis

Sun, R., Kong, B., Yang, N., Cao, B., Feng, D., Yu, X., Ge, C., Feng, S., Fei, F., Huang, J., et al. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.000215 · Cited by 50 · see citing works

Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review

Cai, Y., Yang, Q., Yu, Y., Yang, F., Bai, R., & Fan, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1283784 · Cited by 46 · see citing works